Consortium Represented at NACFC 2015 in Phoenix

Wednesday, October 7th 2015

Print this page

CFF_Logo.jpgThe 29th North American Cystic Fibrosis Conference starts tomorrow (08/10) in Phoenix. The Consortium will be well represented in what promises to be an exciting conference following a landmrk year for CF research. The Vertex clinical trial data and our own gene therapy clinical trial results will be prominently discussed.

The Consortium has four abstracts being presented at the meeting, two on data from the clinical trial and two on our Wave II Lentiviral research. Professor Eric Alton will present a talk on the clnical trial results in a session on Thursday morning and Prof Uta Griesenbach has a poster on some interesting immunology results from the trial.

Professor Steve Hyde and Uta also have two posters on the production and clinical development of our lentiviral vector. 

Professor Alton will also be chairing a rountable discussion on Saturday titled 'Recent Advances in Gene Therapy Relevant to Treatment of CF Lung Disease'. The full Conference schedule can be found here.

 

The North American Cystic Fibrosis Conference, Phoenix. 10-08 to 10-10.

  1. A randomized, double-blind, placebo-controlled trial of repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis. Alton EW et al.
  2. Repeated Administration of the Non-Viral Gene Transfer Agent pGM169/GL67A Does Not Induce Anti-CFTR or Anti-Plasmid Immunoresponses. Griesenbach U et al.
  3. Moving lentiviral-based gene therapy into a first-in-man CF trial. Griesenbach U et al.
  4. Production of rSIV-F/HN: a new Lentivirus vector for CF gene therapy. Hyde SC et al.

 

NACFC_2015_Phoenix.jpg


 

Proposed 3D model of the CFTR protein.

 

A cake that only some of us got to enjoy!

 

A CFTR Western blot, to confirm protein production in cell culture.

 

A pellet of E.coli containing a plasmid expressing a pink fluorescent protein.